A Randomized, Multi-Center, Double Blind, 3 Arm, Phase I/II Pilot Study to Evaluate the Safety and Efficacy of Treatment With ORA102 Combined With Avastin (Bevacizumab) Versus Avastin Alone, in Patients With Neovascular Age Related Macular Degeneration (AMD)

NCT00745511 Phase 1/Phase 2 UNKNOWN

This is s randomized, multi-center, double blind, 3 arm, phase I/II pilot study to evaluate the safety and efficacy of treatment with ORA102 combined with Avastin (Bevacizumab) versus Avastin alone, in patients with neo-vascular age related macular degeneration (AMD).

Details

Lead sponsor	Ora Bio Ltd.
Phase	Phase 1/Phase 2
Status	UNKNOWN
Enrolment	96
Start date	2009-03
Completion	2010-06

Conditions

• Macular Degeneration

Interventions

• ORA102 and Avastin
• Avastin

Primary outcomes

• The incidence and severity of ocular adverse events, including retinal detachment, increase in IOP, cataract, tearing of the retina, decrease in vision, RPE atrophy, and vitreous hemorrhage, will be evaluated. — 32 weeks

Countries

Israel